---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-004555"
form_type: "8-K"
ticker: "CRVO"
cik: "0001053691"
company_name: "CervoMed Inc."
filed_at: "2026-02-18T23:59:59+00:00"
generated_at: "2026-05-16T01:55:44.281355+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# CervoMed's neflamapimod selected for UK EXPERTS-ALS platform for ALS trial

## Summary
- Neflamapimod will be evaluated in EXPERTS-ALS, funded by UK NIHR and motor neuron disease charities, costs covered externally.
- Initial phase: ~35 ALS patients for 18-24 weeks measuring neurofilament light chain (NfL) biomarker; potential expansion to 80.
- First patient with ALS expected to be dosed by end of 2026; trial sponsored by Sheffield Teaching Hospitals NHS Foundation Trust.
- CervoMed maintains primary focus on dementia with Lewy bodies (DLB); Phase 3 in DLB planned to start later in 2026.
- Inclusion based on neflamapimod's p38 inhibition, ability to cross BBB, and positive prior clinical safety/biomarker data.

## SEC filing metadata
- accession: 0001437749-26-004555
- form_type: 8-K
- ticker: CRVO
- cik: 0001053691
- company_name: CervoMed Inc.
- filed_at: 2026-02-18T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1053691/000143774926004555/0001437749-26-004555-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1053691/000143774926004555/crvo20260218_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-004555
- JSON: https://secwatch.observer/filing/0001437749-26-004555.json
- Plain text: https://secwatch.observer/filing/0001437749-26-004555.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.